Short communication · Oct 2021
Conference abstractPublished 27 Feb 2017
Using plural phages to treat Multiple Drug Resistant (MDR) Acinetobacter baumannii
Rangsit University, Thailand
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Acinetobacter baumannii (AB) is one of the important multiple drug resistant (MDR) bacterial infection with environmental contamination especially in hospitals. AB is the major fatal cause of acquired hospital bacterial infection. With the limitation to develop new antibiotic drug, nowadays, phage therapy is reignited as an alternative strategy to fight against MDR bacterium. One of the main problems concerning phage therapy is that bacterium can develop to be a lysogen which becomes resistant to the same phage treatment. This lysogenic mechanism is regulated when bacterium host is infected by temperate phage which unfortunately seems to be the major kind of isolated phages by various researchers. It is seldom to isolate virulent phage which can keep re-infecting the bacterial host by the phageâÂ?Â?s progeny without lysogenic pathway. Using the proper amounts of temperate phage, so called multiplicity of infection (MOI), to infect the bacterial hosts can theoretically prevent lysogenic pathway. However, it is not practical to perfectly prepare the proper amount of MOI for the treatment. In this study, many isolated ABs have been obtained from patients. The AB 116 and AB 160 are used as the models to study their susceptibility to phage therapy. Plural kinds of AB-phages (bacteriophages of AB) for each particular AB have also been isolated and called AB-phage a, b, c and d. AB-phage a and c can infect AB 116 while AB 160 can be infected by AB-phage a, b and d. In this presentation, using plural AB-phage to treat AB in vitro will be presented and discussed.
Subjects
Pharmaceutical SciencesAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Conference abstract
In-vivo efficacy of a bacteriophage cocktail for the control of multiple drug-resistant (MDR) Acinetobacter baumannii infection of lungs
Short communication · 27 Jun 2019
In silico and Mass Spectrometric Characterization of Hpa2-ACO-Kan ternary complex of MDR Acinetobacter baumannii
Short communication · 31 Jan 2020
Risk Factor Analysis of Pan-drug Resistant Acinetobacter baumannii-induced Ventilator-associated Pneumonia in ICU
Conference abstract · 22 Feb 2018
The major risk factors and outcomes of extensively drug-resistant Acinetobacter baumannii acquisition in a Moroccan surgical intensive care unit
More from this journal
The newest in Pharmacoeconomics: Open Access.
Opinion · 1 Dec 2025
Drug Repurposing: Economic Gains, Faster Pathways, Rare Diseases
Short communication · 1 Dec 2025
Preventive Drugs for Older Adults: Health and Economic Benefits
Brief report · 29 Nov 2025
Value Assessment Of High-cost Specialty Drugs
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalPharmacoeconomics: Open Access
- SubjectPharmaceutical Sciences
- BylineArticles whose byline prints “Tirasak Pasharawipas”

